Time to Buy: VIVUS?

In this entry, David and Austin focus on VIVUS, which saw shares clobbered in July. Is it time to invest in this cutting-edge company on the cheap, or is the poor month a sign of further troubles ahead? Watch and find out.

When it comes to do-or-die busineses, the biotech industry takes the cake. Arena Pharmaceuticals is one recent success story in the industry after gaining FDA approval for its innovative obesity drug. While the future looks bright for Arena, though, there are still plenty of obstacles ahead. In our brand-new premium research report on Arena Pharmaceuticals, we walk investors through the must-know opportunities and threats facing the company. Since key news can develop quickly, we're also including a full year of updates for those who sign up. Click here now to learn more.

 

 

 

Austin Smith, Dave Williamson, and The Motley Fool have no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (1) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On August 12, 2012, at 6:56 PM, Foreeverlong wrote:

    With all due respect to VIVUS investors, I would not invest in VIVUS. One of its key ingredients (topiramate) is inherently problematic with histiorical problems of birth defects, loss of memory etc. Further, the principal componens of Qsymia (Phentermine and Topiramate) have been available for years for physicians to prescribe to their patients, and they have not done so. Why would they now begin to do so in a more expense combination.

    While Qsymia received approval from the FDA, it did so with a very restrictive REMS. It also, makes me very nervous when senior management has been peeling off major volumes of their shares and selling them into the market. So, while they are telling you to buy in....they are selling off their shares!

    Conclusion: I don't think there is any question, that the stock to invest in for this sector is Arena (ARNA), and their novel drug, Belviq.

Add your comment.

DocumentId: 1981581, ~/Articles/ArticleHandler.aspx, 4/16/2014 6:19:05 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement